p53 loss of heterozygosity (LOH) is a frequent event in tumors of somatic and Li-Fraumeni syndrome patients harboring p53 mutation. Here, we focused on resolving a possible crosstalk between the immune-system and p53 LOH. Previously, we reported that p53 heterozygous bone-marrow mesenchymal progenitor cells undergo p53 LOH in-vivo. Surprisingly, the loss of either the wild-type p53 allele or mutant p53 allele was detected with a three-to-one ratio in favor of losing the mutant allele. In this study, we examined whether the immune-system can affect the LOH directionality in bone marrow progenitors. We found that mesenchymal progenitor cells derived from immune-deficient mice exhibited the same preference of losing the mutant p53 allele as immune-competent matched cells, nevertheless, these animals showed a significantly shorter tumor-free survival, indicating the possible involvement of immune surveillance in this model. Surprisingly, spontaneous tumors of p53 heterozygous immune-deficient mice exhibited a significantly higher incidence of p53 LOH compared to that observed in tumors derived of p53 heterozygous immune-competent mice. These findings indicate that the immune-system may affect the p53 LOH prevalence in spontaneous tumors. Thus suggesting that the immune-system may recognize and clear cells that underwent p53 LOH, whereas in immune-compromised mice, those cells will form tumors with shorter latency. In individuals with a competent immune-system, p53 LOH independent pathways may induce malignant transformation which requires a longer tumor latency. Moreover, this data may imply that the current immunotherapy treatment aimed at abrogating the inhibition of cellular immune checkpoints may be beneficial for LFS patients.
The function of the tumor suppressor p53 is abrogated in most human cancers, 1 typically by a missense mutation in the coding sequence of one of its alleles. In most cases, the remaining wild allele (WT) p53 allele is lost in a process named loss of heterozygosity (LOH). 2 Exposure to various types of cellular insults leads to stabilization and accumulation of the mutant p53 (Mutp53) protein, which gains novel oncogenic activity that facilitates cellular transformation. This unique phenomenon is termed oncogenic gain of function. 3, 4 Germ-line mutations in p53 are associated with the rare familial cancer predisposition Li-Fraumeni syndrome (LFS). 5 The LFS patients develop early onset of neoplasms, predominantly sarcomas and breast carcinomas, as well as brain tumors and adrenocortical carcinomas. 6 It is now well accepted that one of the hallmarks of cancer is the ability of malignant cells to escape immune surveillance. 7 Accordingly, recent breakthroughs in cancer therapy are aimed at abrogating the inhibition of cellular immune checkpoints. This clearly reiterate the importance of the immune system in elimination of cancerous cells. 8 Interestingly, it was shown that the presence of Mutp53 specific antibodies could be detected in sera of cancer patients, 9, 10 suggesting a humoral response aimed against Mutp53. However, to date no direct link between immune response and mutant p53 mediated transformation was evident. Previously, in order to study p53 LOH we used LFS murine model, harboring R172H Mutp53 that is homologous to human R175H hot-spot mutation. 11 This cohort of mice predominantly develop sarcomas and lymphomas within 15-18 months, whereas two third of spontaneous tumors undergoes p53 LOH. 11 Due to high prevalence of Sarcomas in our animal model and LFS patients, which are of mesenchymal origin we focused our studies on mesenchymal stem cells that were proposed as the cells of origin of mesenchymal neoplasms. We found that p53 heterozygous (HZp53) mesenchymal bonemarrow (BM) progenitor cells undergo p53 LOH in-vivo. 12 Surprisingly, the loss of either the WT or the mutant p53 alleles was detected with a ratio of three to one in favor of losing the mutant allele. Although this was the first report on the loss of the Mutp53 allele through LOH in an apparent healthy tissue, Mutp53 LOH was once noticed in two Li-Fraumeni tumors 13 and in other TSGs with a role in DNA repair. [14] [15] [16] [17] [18] We hypothesized that the outcome of dual LOH is a result of either cellular intrinsic mechanism or the byproduct of elimination of cells that underwent WTp53 LOH by the immune system.
In this study, we addressed the question of whether the immune system can recognize and eliminate BM progenitors that underwent WTp53 LOH. Herein, we established a novel Rag1 null Il2rg null immune deficient (ID) mice carrying HZ p53 R172H and matched immune competent (IC) siblings. We detected p53 LOH in all examined spontaneous tumors derived from HZp53 ID mice, whereas only two thirds of tumors obtained from HZp53 IC mice exhibited p53 LOH. Indeed, HZp53 ID mice showed significantly shorter tumorfree survival, indicating the important role of immune surveillance in this model. As far as we know, this is the first report linking LOH and immune surveillance. These findings imply that the immune system may affect the prevalence of p53 LOH during the development of spontaneous tumors.
Material and Methods

Mice strains
The following mice strains were used in this study: C57BL/6 HZp53 for p53 R172H (kindly provided by Professor G. Lozano) and NOD.Cg-Rag1 tm1Mom
Il2
rgtm1Wjl /SzJ ID mice (The Jackson Laboratory, Sacramento, CA). ID mice lacking Rag1/ Il2rg have diminished number of Th, Tc, B, macrophages and NK cells in their spleen. 19 These strains were crossed to create mice which are ID and IC HZp53. Animal protocols were approved by the Institutional Animal Care and Use Committee of the Weizmann Institute of Science.
Preparation of BM cells suspension: colony-forming unitsfibroblasts (CFU-fs) CFU-fs were established as previously described 12 from BM nucleated cells from femurs and tibias of 6-13 months IC (n 5 6) and ID (n 5 6) HZp53 mice. Cells were incubated at 378C in a humidified atmosphere of 10% CO 2 and re-fed once a week without further treatment. At 14-21 days, un-fixed colonies were subjected to quantitative genomic DNA genotyping.
Genomic DNA extraction DNA was extracted using QUICK gDNA Miniprep (Zymo Research, Irvin, CA), according to manufacturer's protocol. The genomic DNA was eluted in double distilled water.
p53 SNP genomic real time melt curve genotyping
The p53 R172H SNP was detected using the SimpleProbe TaqMan assay (Roche, Switzerland) according to the manufacturer's protocol. Known percentage of WTp53 and Mutp53 DNA samples were mixed to create a six points' standard curve for the unknown samples. The fluorescence was measured using the LightCycler 
Melt-curve genotyping analysis
Analysis was performed using an algorithm that was developed with the help of Alex Kagan from the physics department. This algorithm detects the melting temperatures local maxima for the WTp53 and Mutp53 alleles and calculates their ratio. This ratio is then compared to the standard curve, resulting in high resolution genotyping of the unknown samples.
Tumor samples
A cohort of mice was monitored for signs of illness or obvious tumor burden. Moribund mice were sacrificed, and tumors were fixed with 4% paraformaldehyde in phosphatebuffered saline. Tissues were paraffin embedded and sectioned at 10 lm. All sections were stained with hematoxylin and eosin prior to pathological analysis.
Statistical analysis
The Prism 5 program (GraphPad Software, San Diego, CA) was used for statistical analysis. Differences were considered statistically significant with a p values <0.05.
Results
Directionality of dual p53 LOH is not a result of immune system clearance p53 LOH is a common phenomenon that facilities malignant transformation. Yet, little is known about the molecular What's new? p53 loss of heterozygosity (LOH) is a frequent event in tumors of somatic and Li-Fraumeni syndrome (LFS) patients harboring p53 mutation. While the ability of malignant cells to escape immune surveillance is well accepted, a possible crosstalk between the immune system and p53 LOH remains to be clarified. This study suggests that the immune system may recognize and clear cells that underwent WTp53 LOH, whereas in immune compromised mice, those cells will form tumors with a reduced latency. Moreover, the data indicate that immunotherapy treatment aimed at abrogating the inhibition of cellular immune checkpoints may be beneficial for LFS patients.
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events occurring in pre-malignant cells that lead to transformation. 12 It is of interest to examine whether the immune system may recognize the WTp53 LOH associated cellular alterations and thus, as a consequence, to execute clearance of these cells. To address this issue we studied ID mice lacking Rag1, which is involved in V(D)J recombination, but not in DNA repair homologues recombination repair pathway. These mice are also deficient in Il2rc. The mice were crossed with Mutp53 R172H harboring mice in order to generate HZp53 ID mice. Fluorescence-activated cell sorting (FACS) analysis indicated the deficiency of T, B and NK cells in the BM of HZp53 ID mice is comparable with the original ID mice colony (Figs. 1c and 1d) . To assess the incidence of p53 LOH and examine whether the immune system has an effect on its directionality we compared CFU-Fs derived from HZp53 IC and HZp53 ID mice using a novel developed quantitative genotyping approach. This technique utilized chemically modified Taqman probe that specifically anneals to either WTp53 or Mutp53 alleles in different temperatures. Consequently, a designated algorithm calculates the percentage of cells within the population that underwent p53 LOH, by comparison of the obtained data to known ratios of WTp53 and Mutp53 alleles. It was found that CFU-Fs derived from HZp53 ID mice underwent p53 LOH in a similar frequency as their counterparts from HZp53 IC mice (Fig.  1) . Furthermore, the trait of a higher frequency of Mutp53 allele loss was detected in CFU-Fs from both HZp53 IC (p values5 0.012) and HZp53 ID mice (p values 5 0.011), suggesting that p53 LOH directionality is not affected by the immune system (Figs. 1a and 1b) .
Immune deficiency accentuates p53 LOH prevalence in spontaneous tumors
The notion that the immune system plays a role in tumor surveillance, 20 was mostly based on studies of carcinogenicinduced mice models, where ID animals display shorter tumor-free survival compared to matched IC animals. Conversely, Rogers et al. reported that adaptive immune system is not efficiently suppressing tumor formation in a Sleeping Beauty (SB) transposon mutagenesis mouse model of spontaneous tumors. 21 Thus, it was interesting to examine whether the immune system affects spontaneous tumor latency and p53 LOH status in spontaneous tumors of p53HZ IC and p53HZ ID mice cohort. For this aim, mice were monitored for tumor appearance. Once tumor appeared, LOH status of the tumor was assessed. p53HZ ID mice showed a significantly shorter tumor-free survival compared to p53HZ IC mice, mean of 50 weeks versus mean of 65 weeks, respectively (Fig. 2a) . This is in agreement with the tumor-free survival that was previously described of double Rag1 p53 deficient mice. 22 Since the latter mice colony lack only B and T cells, this suggests that these are the cells that are crucial for immune-surveillance in the absence of p53. The tumor spectra of the novel crossed bread colony of ID/IC mice with C57BL/6 -NOD background was similar to the original C57BL/6, including soft-tissue and osteosarcomas, lymphomas, adeno and squamous-cell carcinoma. However, the incidence of carcinomas was much more prevalent in p53HZ ID mice compared with p53HZ IC mice, 50% (n 5 14) versus 17% (n 5 23), respectively (Supporting Information Table 1) .
Surprisingly, in contrast to HZp53 original mice colony and in LFS patients about two third of tumors undergo p53 LOH 11, 23 all tumors derived from p53HZ ID mice underwent p53 LOH (n 5 9) compared with only 66.7% of tumors derived from p53HZ IC mice that exhibited p53 LOH (Fig.  2b, p values 5 0.044) . This may indicate that the immune system can recognize and clear cells that underwent p53 LOH, whereas in its absence, those cells will form tumors in shorter latency. In an individual with a competent immune system, either mice or theoretically LFS patient, other pathways are utilized in the transformation process which takes longer period of time to form tumors (Fig. 3) .
Discussion
Most LFS patients harbor a mutated p53 allele in their germline. 5 Although these individuals develop normally, they have a high risk to develop tumors, with an incidence of 40-60% of tumors undergo p53 LOH. 13 Soft-tissue and bone sarcomas, which are of mesenchymal origin are predominant in LFS families. 6 The intriguing findings that BM progenitors derived from HZp53 IC mice undergo bi-directional p53 LOH in-vivo with higher incidence of losing the Mutp53 allele 12 led us to examine whether the immune system plays a role in eliminating pre-malignant cells following p53 LOH. Early studies in the field of p53 detected antibodies against p53 in patients' serum, 9 indicating a humoral response against p53. We hypothesized that the loss of either WTp53 or Mutp53 allele is stochastic. While upon WTp53 loss the cell undergoes cellular alterations that are recognized by the immune system that eliminates them, thus leaving higher percentage of cells that lost the Mutp53 allele. However, when we examined this hypothesis by using CFU-Fs derived HZp53 immune deficient mice, the same preference of losing the Mutp53 allele were found. This finding may indicate that the adaptive immune system does not play a role in the elimination of cells that lost WTp53. Still, it could also be that the NK cells, which are part of the innate immune system, despite being in reduced numbers, cleared those cells. Another possibility may be that cell autonomous death is triggered following the loss of WT p53, despite the presence of mutant p53. Further research is needed to resolve this question.
Another intriguing observation in LFS research is the strikingly high prevalence of soft-tissue and osteosarcomas in these patients, 30% versus 1% of all adult solid malignant cancers. 6, 24 It was demonstrated that alternative genetic background of distinct mouse colonies knocked-in with Mutp53
R172H affects the spectrum of developing tumors types. For example, HZ p53 C57BL/6 mice predominantly develop sarcomas and lymphomas, 11 whereas HZp53 129S/Sv develop a variety of carcinomas, soft tissue and bone sarcomas, leukemia, and even a glioblastoma multiforme. 23 Furthermore, backcrossing HZp53 C57BL/6 mice to BALB/C background gave rise to mostly osteosarcomas and mammary carcinomas. 25 Herein, our specific established mice colony of ID/IC HZp53 generated by crossing C57BL/6 and NOD background exhibited similar tumor trait as their progeny, the C57BL/6 HZp53 genotype. Indeed, they share a similar tumor spectra and tumor-free survival. However the percentage of adeno-and squamous cell carcinomas was elevated, suggesting that C57BL/6 background has an intrinsic resistance to carcinomas, as suggested before. 26 The two colonies, the progeny C57BL/6 HZp53 and the novel C57BL/6/NOD IC HZp53, showed similar incidence of p53 LOH and its directionality in BM progenitors, suggesting that this phenomenon is background independent. Interestingly, HZp53 ID mice of our cohort exhibited shorter tumor free survival and augmented prevalence of p53 LOH in spontaneous tumors compared to their IC counterparts. Pathological analysis revealed that these traits are not mediated by increased cell growth or decreased cell death in ID mice compared to IC mice (Supporting Information Table  1 ). Thus, it is tempting to speculate that in HZp53 ID mice, cells that have lost WTp53 generate tumors in a shorter latency compared to IC mice as a result of immunesurveillance, elimination of cells that lost the WTp53. It is plausible that cells, which evade the immune system, develop additional genetic aberrations, which require time to evolve, thus mice have a longer tumor free survival and lower percentage of tumors that underwent p53 LOH. This suggests that immune checkpoints inhibitors, such as anti-PD1 or anti-CTLA-4, which showed remarkable results in clinical trials 27 may augment the immune response against premalignant cells that underwent p53 LOH in LFS patients. Therefore, immune checkpoints blockade could be utilize both for prevention and treatment of LFS patient. However, current FDA-approved tumor types, that is, melanoma, squamous cell carcinoma, renal cell carcinoma and classical Hodgkin lymphoma 27 do not overlap with LFS tumor spectra. Second, as a preventative medicine, the costly treatment and adverse effects argue against this notion. Yet, the diverse capability and lasting effects of this therapy may be beneficial as a first-line treatment of first tumor, which may prevent frequently occurring second or third tumors in those patients. Giving together, this appears to be the first report linking LOH prevalence and immune surveillance. Furthermore, the shorter tumor-free survival in HZp53 ID mice may implicate that augmentation of the immune response against tumors of LFS patients may benefit from the current immune therapy aimed against the inhibition of immune checkpoints.
